Literature DB >> 27496305

Clinical presentation and staging of Hodgkin lymphoma.

Andrea Gallamini1, Martin Hutchings2, Safaa Ramadan3.   

Abstract

In the present chapter the authors present a brief overview of the diagnostic methods proposed over time for Hodgkin lymphoma (HL) spread detection, moving from surgical procedures, through standard radiological and functional imaging techniques to the present state of the art for HL staging. The main body of the review will be dedicated to the recently published guidelines for lymphoma staging (including HL) agreed by the experts during the 12th International Congress for Malignant Lymphoma in Lugano. The recommendations of the panel on how to integrate flurodeoxyglucose positron emission tomography (FDG-PET) scan in the armamentarium of staging procedures will be presented and commented, with a special emphasis on the utility of special procedures, such as bone marrow trephine biopsy, which is deemed no longer needed in the PET era. While the HL diagnosis is straightforward in most cases, sometimes HL is a subtle disease, difficult to diagnose for the paucity of symptoms, the absence of physical findings, or for concomitant immunologic disorders: a compete overview of the common and rare patterns of HL clinical presentation will be also offered. The future perspective of PET scan use will be based on a operator-independent, quantitative readings of the scan thanks to a plethora of sophisticated dedicated software, which are now available, able to quantify every voxel captured by the tumor to display the metabolically active tumor volume. Moreover, new tracers are now available able to track the new pathways of cellular metabolism beside glycolysis such as amino acids or purine-analogues or specific oncoproteins; the preliminary, promising results will be reported. Preliminary results from other imaging techniques, such as diffusion-weighted magnetic resonance (DW-MRI) will be also reported.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hodgkin lymphoma; PET; Presentation; Staging

Mesh:

Year:  2016        PMID: 27496305     DOI: 10.1053/j.seminhematol.2016.05.005

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

1.  MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.

Authors:  Antonella Caivano; Francesco La Rocca; Vittorio Simeon; Marco Girasole; Simone Dinarelli; Ilaria Laurenzana; Angelo De Stradis; Luciana De Luca; Stefania Trino; Antonio Traficante; Giovanni D'Arena; Giovanna Mansueto; Oreste Villani; Giuseppe Pietrantuono; Luca Laurenti; Luigi Del Vecchio; Pellegrino Musto
Journal:  Cell Oncol (Dordr)       Date:  2016-10-19       Impact factor: 6.730

2.  18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma: A Prospective Study with 18F-FDG PET/CT as the Reference Standard.

Authors:  Martijn V Verhagen; Leon J Menezes; Deena Neriman; Tom A Watson; Shonit Punwani; Stuart A Taylor; Ananth Shankar; Stephen Daw; Paul D Humphries
Journal:  J Nucl Med       Date:  2021-02-19       Impact factor: 10.057

3.  A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.

Authors:  Karan L Chohan; Jason R Young; Scott Lester; Muhamad Alhaj Moustafa; Allison Rosenthal; Han W Tun; Bradford S Hoppe; Patrick B Johnston; Ivana N Micallef; Thomas M Habermann; Stephen M Ansell
Journal:  Blood Adv       Date:  2022-07-26

4.  PET/CT imaging in management of concomitant Hodgkin lymphoma and tuberculosis - a problem solver tool.

Authors:  Nina Jehanno; Thibaut Cassou-Mounat; Anne Vincent-Salomon; Marie Luporsi; Manel Bedoui; Frédérique Kuhnowski
Journal:  Clin Case Rep       Date:  2017-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.